DeutschNewstral
Article
Bbarrons.com on 2021-07-19 16:23
Biogen Is Still a Buy Despite Alzheimer's Drug Concerns, Analyst Says2 min read
Related news
- BBiogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug2 min readbarrons.com
- BAlzheimer's Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off. 4 min readbarrons.com
- BAnalyst Raises Price Targets on 3 Smaller Alzheimer's Stocks2 min readbarrons.com
- MJPMorgan's NII outlook was 'unnecessarily confusing,' analyst says2 min readmarketwatch.com
- MFDA stalled on CBD for now, analyst says2 min readmarketwatch.com
- MNIO stock is 'bottoming out,' analyst says2 min readmarketwatch.com
- BAcknowledging Concerns Over Biogen's Alzheimer's Drug, FDA Asks for Investigation2 min readbarrons.com
- MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min readmarketwatch.com
- MBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK4 minmarketwatch.com
- BBiogen Stock Is Tumbling Because Its Alzheimer's Drug Rollout Isn't Going So Well2 min readbarrons.com
- BChipotle’s Earnings Power Can Keep the Stock Rallying, Analyst Says2 min readbarrons.com
- BA Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug 2 minbarrons.com
- MMicron's recovery from 'worst memory downturn in 13 years' will take time, analyst says2 min readmarketwatch.com
- BAMD's Stock Pullback and PC Share Gains Makes It a Buy, Analyst Says2 min readbarrons.com
- MFedEx set to benefit from Yellow’s demise, analyst says2 min readmarketwatch.com
- BBiogen Is Giving Away Its Controversial Alzheimer's Drug: Report 2 min readbarrons.com
- BBiogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO1 min readbarrons.com
- BBiogen in Pole Position After Roche's Alzheimer's Drug Disappoints3 min readbarrons.com
- BBed Bath & Beyond Faces Near-Term Headwinds, Analyst Says2 min readbarrons.com
- MRivian's stock rallies as EV sales are 'ramping well,' analyst says2 min readmarketwatch.com